Patents by Inventor Mario Waser

Mario Waser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for the manufacture of isavuconazole or ravuconazole
    Patent number: 10590092
    Abstract: The invention relates to a process for the manufacture of diastereomerically and enantiomerically enriched triazole compounds isavuconazole and ravuconazole, comprising a Reformatsky reaction between a ketone and a 2-halozincpropionate ester, followed by a resolution step, preferably an enzymatic resolution with an esterase enzyme.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: March 17, 2020
    Assignee: Basilea Pharmaceutica AG
    Inventors: Ruben Van Summeren, Harrie Vaessen, Daniel Mink, Mario Waser
  • PROCESS FOR THE MANUFACTURE OF ISAVUCONAZOLE OR RAVUCONAZOLE
    Publication number: 20190077771
    Abstract: The invention relates to a process for the manufacture of diastereomerically and enantiomerically enriched triazole compounds isavuconazole and ravuconazole, comprising a Reformatsky reaction between a ketone and a 2-halozincpropionate ester, followed by a resolution step, preferably an enzymatic resolution with an esterase enzyme.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 14, 2019
    Inventors: Ruben Van Summeren, Harrie Vaessen, Daniel Mink, Mario Waser
  • Process for the manufacture of isavuconazole or ravuconazole
    Patent number: 9783508
    Abstract: The invention relates to a process for the manufacture of diastereomerically and enantiomerically enriched triazole compounds isavuconazole and ravuconazole, comprising a Reformatsky reaction between a ketone and a 2-halozincpropionate ester, followed by a resolution step, preferably an enzymatic resolution with an esterase enzyme.
    Type: Grant
    Filed: July 31, 2013
    Date of Patent: October 10, 2017
    Assignee: Basilea Pharmaceutica AG
    Inventors: Ruben Van Summeren, Harrie Vaessen, Daniel Mink, Mario Waser
  • PROCESS FOR THE MANUFACTURE OF ISAVUCONAZOLE OR RAVUCONAZOLE
    Publication number: 20150239852
    Abstract: The invention relates to a process for the manufacture of diastereomerically and enantiomerically enriched triazole compounds isavuconazole and ravuconazole, comprising a Reformatsky reaction between a ketone and a 2-halozincpropionate ester, followed by a resolution step, preferably an enzymatic resolution with an esterase enzyme.
    Type: Application
    Filed: July 31, 2013
    Publication date: August 27, 2015
    Inventors: Ruben Van Summeren, Harrie Vaessen, Daniel Mink, Mario Waser
  • Iejimalid analoga and uses thereof
    Patent number: 8431724
    Abstract: The invention relates to Iejimalides having the following formula (I) in which a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p are simple or double bonds, the continuous lines representing at least one simple bond, the dotted lines representing a possible bond. A double bond can be present but it is not necessary, and provided that a continuous line is also present, or a simple bond can be present if no other line is represented; m=0-20 and n1-n18=1, 2. The bonds can be used as chemotherapeutic agents for treating cancer.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: April 30, 2013
    Assignee: Studiengesellschaft Kohle mbH
    Inventors: Alois Fürstner, Christina Nevado-Blàzquez, Mario Waser, Emilie Moulin, Christophe Aïssa
  • IEJIMALID ANALOGA AND USES THEREOF
    Publication number: 20100056616
    Abstract: The invention relates to Iejimalides having the following formula (I) in which a, b, c, d, e, f, g, h, i, j, k, l, m, n, o, p are simple or double bonds, the continuous lines representing at least one simple bond, the dotted lines representing a possible bond. A double bond can be present but it is not necessary, and provided that a continuous line is also present, or a simple bond can be present if no other line is represented; m=0-20 and n1-n18=1, 2. The bonds can be used as chemotherapeutic agents for treating cancer.
    Type: Application
    Filed: March 5, 2008
    Publication date: March 4, 2010
    Inventors: Alois Fürstner, Christina Nevado-Blàzquez, Mario Waser, Emilie Moulin, Christophe Aïssa